Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
Pyxis Oncology Inc (PYXS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/26/2025: PYXS (4-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $7.17
1 Year Target Price $7.17
| 4 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 493.48% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 12/26/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 69.11M USD | Price to earnings Ratio - | 1Y Target Price 7.17 |
Price to earnings Ratio - | 1Y Target Price 7.17 | ||
Volume (30-day avg) 7 | Beta 1.38 | 52 Weeks Range 0.83 - 5.55 | Updated Date 12/28/2025 |
52 Weeks Range 0.83 - 5.55 | Updated Date 12/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.58 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -2930.25% |
Management Effectiveness
Return on Assets (TTM) -34.33% | Return on Equity (TTM) -87.28% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 11930278 | Price to Sales(TTM) 24.51 |
Enterprise Value 11930278 | Price to Sales(TTM) 24.51 | ||
Enterprise Value to Revenue 4.23 | Enterprise Value to EBITDA 1.09 | Shares Outstanding 62264215 | Shares Floating 41131118 |
Shares Outstanding 62264215 | Shares Floating 41131118 | ||
Percent Insiders 23.29 | Percent Institutions 38.75 |
Upturn AI SWOT
Pyxis Oncology Inc
Company Overview
History and Background
Pyxis Oncology Inc. was founded in 2017. It is a clinical-stage biotechnology company focused on developing novel immunotherapies for cancer. Its evolution has been driven by its pipeline of investigational antibody-drug conjugates (ADCs) and other targeted therapies designed to selectively target and eliminate cancer cells.
Core Business Areas
- Oncology Therapeutics Development: Pyxis Oncology is primarily engaged in the research, development, and potential commercialization of its pipeline of novel antibody-drug conjugates (ADCs) and other targeted therapies for the treatment of various cancers. Their focus is on leveraging these innovative modalities to address unmet medical needs in oncology.
Leadership and Structure
Pyxis Oncology Inc. is led by a management team with expertise in drug development and biotechnology. The organizational structure is typical of a clinical-stage biopharmaceutical company, with departments focused on research and development, clinical operations, regulatory affairs, and business development.
Top Products and Market Share
Key Offerings
- PYX-201: PYX-201 is an investigational antibody-drug conjugate (ADC) designed to target and kill cancer cells. Its development is a core focus for Pyxis Oncology. Specific market share data is not yet applicable as it is in clinical development. Key competitors in the ADC space include companies like Seagen (now Pfizer), Daiichi Sankyo, and Gilead Sciences.
- PYX-301: PYX-301 is another investigational ADC in Pyxis Oncology's pipeline, also aimed at treating various forms of cancer. Similar to PYX-201, market share is not yet a factor. The competitive landscape for novel oncology ADCs is intense, with many companies developing therapies in this area.
Market Dynamics
Industry Overview
The oncology therapeutics market is a rapidly growing and highly competitive sector within the pharmaceutical industry. Key trends include the advancement of targeted therapies, immunotherapies, and personalized medicine. There is a significant unmet need for effective treatments for many advanced cancers.
Positioning
Pyxis Oncology is positioned as a clinical-stage biopharmaceutical company seeking to develop novel ADC therapies. Its competitive advantage lies in its proprietary ADC technology and pipeline, aiming to offer differentiated treatment options for cancer patients. However, as a clinical-stage company, it faces significant risks related to clinical trial success and regulatory approval.
Total Addressable Market (TAM)
The total addressable market for oncology drugs is in the hundreds of billions of dollars globally and continues to grow. Pyxis Oncology, with its focus on specific cancer indications, aims to capture a portion of this market with its innovative therapies. Its current positioning is early-stage, focusing on demonstrating clinical efficacy to establish its presence.
Upturn SWOT Analysis
Strengths
- Proprietary antibody-drug conjugate (ADC) technology.
- Pipeline of novel investigational therapies for cancer.
- Experienced management team in drug development.
- Focus on addressing unmet medical needs in oncology.
Weaknesses
- Clinical-stage company with no approved products.
- High reliance on successful clinical trial outcomes.
- Significant cash burn due to R&D expenses.
- Limited brand recognition and market presence.
Opportunities
- Advancements in oncology treatment modalities.
- Growing demand for novel cancer therapies.
- Potential for strategic partnerships and collaborations.
- Expansion of the ADC market.
Threats
- Failure of clinical trials to demonstrate efficacy or safety.
- Regulatory hurdles and delays in drug approval.
- Intense competition from established pharmaceutical companies and other biotechs.
- Changes in healthcare reimbursement policies.
- Intellectual property challenges.
Competitors and Market Share
Key Competitors
- Seagen Inc. (SGEN)
- Gilead Sciences, Inc. (GILD)
- Daiichi Sankyo Company, Limited (DSNKY)
- Merck & Co., Inc. (MRK)
Competitive Landscape
Pyxis Oncology Inc. faces a highly competitive landscape in the oncology ADC market. Established players like Seagen and Daiichi Sankyo have approved products and significant market share. Pyxis's advantage lies in its novel targets and conjugates, but it must overcome the established presence and resources of its competitors.
Growth Trajectory and Initiatives
Historical Growth: Pyxis Oncology Inc.'s historical growth has been driven by its progress in advancing its preclinical and clinical-stage programs, as well as its ability to secure funding through equity offerings. The company has expanded its operational capacity and research efforts since its inception.
Future Projections: Future growth projections for Pyxis Oncology Inc. are contingent upon the successful development and regulatory approval of its lead drug candidates. Analyst estimates would focus on potential peak sales of its pipeline assets, factoring in market penetration and competitive dynamics. However, these projections carry significant uncertainty.
Recent Initiatives: Recent initiatives likely include the progression of its clinical trials for PYX-201 and PYX-301, potential strategic partnerships, and ongoing efforts to secure additional funding to support its development programs.
Summary
Pyxis Oncology Inc. is a clinical-stage biotechnology company with a promising pipeline of antibody-drug conjugates for cancer treatment. Its core strength lies in its innovative technology and focus on unmet medical needs. However, the company faces significant risks associated with clinical trial success, regulatory approval, and intense competition. Continued investment in R&D and successful demonstration of clinical efficacy are crucial for its future growth and survival.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Financial News Websites
- Biotechnology Industry Reports
- ClinicalTrials.gov
Disclaimers:
This analysis is based on publicly available information and should not be considered investment advice. Financial data and market share figures are estimates and subject to change. Pyxis Oncology Inc. is a clinical-stage company, and investments in such companies carry significant risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Pyxis Oncology Inc
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2021-10-08 | CEO, President, Chief Medical Officer & Director Dr. Lara S. Sullivan M.D., MBA | ||
Sector Healthcare | Industry Biotechnology | Full time employees 44 | Website https://www.pyxisoncology.com |
Full time employees 44 | Website https://www.pyxisoncology.com | ||
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients with several cancer indications, which is in Phase 2 clinical trial for the treatment of tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and pancreatic ductal adenocarcinoma. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates, including micvotabart pelidotin and PYX-203, and other ADC product candidates directed to the licensed targets; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.